Online citations, reference lists, and bibliographies.
← Back to Search

Nasal Delivery Of High Molecular Weight Drugs

Y. Ozsoy, S. Gungor, E. Cevher
Published 2009 · Medicine, Chemistry

Cite This
Download PDF
Analyze on Scholarcy
Share
Nasal drug delivery may be used for either local or systemic effects. Low molecular weight drugs with are rapidly absorbed through nasal mucosa. The main reasons for this are the high permeability, fairly wide absorption area, porous and thin endothelial basement membrane of the nasal epithelium. Despite the many advantages of the nasal route, limitations such as the high molecular weight (HMW) of drugs may impede drug absorption through the nasal mucosa. Recent studies have focused particularly on the nasal application of HMW therapeutic agents such as peptide-protein drugs and vaccines intended for systemic effects. Due to their hydrophilic structure, the nasal bioavailability of peptide and protein drugs is normally less than 1%. Besides their weak mucosal membrane permeability and enzymatic degradation in nasal mucosa, these drugs are rapidly cleared from the nasal cavity after administration because of mucociliary clearance. There are many approaches for increasing the residence time of drug formulations in the nasal cavity resulting in enhanced drug absorption. In this review article, nasal route and transport mechanisms across the nasal mucosa will be briefly presented. In the second part, current studies regarding the nasal application of macromolecular drugs and vaccines with nano- and micro-particulate carrier systems will be summarised.
This paper references
10.1021/bm800975j
New generation of hybrid poly/oligosaccharide nanoparticles as carriers for the nasal delivery of macromolecules.
D. Teijeiro-Osorio (2009)
10.1016/S0169-409X(01)00166-1
Intranasal vaccination against plague, tetanus and diphtheria.
H. O. Alpar (2001)
10.1016/S0169-409X(97)00049-5
Preparation of microspheres by the solvent evaporation technique.
McGinity (1997)
10.1016/J.FARMAC.2005.08.004
Nasal administration of heparin-loaded microspheres based on poly(lactic acid).
A. Yildiz (2005)
10.1016/S0168-3659(99)00271-0
Evaluation of starch-maltodextrin-Carbopol 974 P mixtures for the nasal delivery of insulin in rabbits.
C. Callens (2000)
10.1016/j.ijpharm.2008.01.015
Pharmacokinetics and pharmacodynamics of exenatide following alternate routes of administration.
B. Gedulin (2008)
10.1023/A:1018946829225
The Effect of Cyclodextrins on the Stability of Peptides in Nasal Enzymic Systems
W. Irwin (2004)
10.1023/B:PHAM.0000032998.84488.7a
Cyclodextrins in Nasal Delivery of Low-Molecular-Weight Heparins: In Vivo and in Vitro Studies
T. Yang (2004)
10.1002/JPS.2600820909
Development of a new drug carrier made from alginate.
M. Rajaonarivony (1993)
10.1002/JPS.10579
Chain length-dependent effects of alkylmaltosides on nasal absorption of enoxaparin.
Fatima Mustafa (2004)
Novel N-Trimethyl Chitosan- Poly(γ-Glutamic Acid) Nanoparticles for Mucosal Delivery of Vaccines
S. K. Salomon (2007)
Molecules
(2009)
10.1016/S0169-409X(97)00063-X
Effects of physicochemical properties and other factors on systemic nasal drug delivery.
Roméo (1998)
J. Pharm. Sci
(1994)
10.1016/J.JCONREL.2005.07.007
Preparation, characterization and nasal delivery of alpha-cobrotoxin-loaded poly(lactide-co-glycolide)/polyanhydride microspheres.
Y. Li (2005)
10.1586/14760584.6.3.401
Implication of nanoparticles/microparticles in mucosal vaccine delivery
S. Vyas (2007)
Bioadhesion of hydrated chitosan: An in vitro and in vivo study
I. Henriksen (1996)
Chitosan as a novel delivery system for vaccines
L. Illum (2001)
10.1016/0378-5173(96)04569-3
Nasal delivery of octreotide: Absorption enhancement by particulate carrier systems
C. Oechslein (1996)
J. Pharm. Sci
(1994)
10.1016/J.JACI.2004.05.026
Heparin attenuates symptoms and mast cell degranulation induced by AMP nasal provocation.
D. Zeng (2004)
10.1016/J.JCONREL.2004.08.010
Recent advances on chitosan-based micro- and nanoparticles in drug delivery.
S. Agnihotri (2004)
10.1042/BST025337S
Potential of particulate carriers for the mucosal delivery of DNA vaccines.
H. O. Alpar (1997)
This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution license
10.1023/A:1015952320372
Drug Absorption Through Mucosal Membranes: Effect of Mucosal Route and Penetrant Hydrophilicity
D. C. Corbo (2004)
10.1002/jps.21493
Pharmaceutical aspects of intranasal delivery of vaccines using particulate systems.
S. Sharma (2009)
10.1002/JPS.2600810710
Effects of enzymatic inhibition and increased paracellular shunting on transport of vasopressin analogues in the rat.
A. Ungell (1992)
10.1016/0378-5173(90)90126-O
Investigation of the nasal absorption of biosynthetic human growth hormone in sheep—use of a bioadhesive microsphere delivery system
L. Illum (1990)
10.1248/BPB.27.1717
Mucoadhesive microspheres for controlled drug delivery.
K. P. Chowdary (2004)
10.1016/S0169-409X(97)00064-1
Optimization of systemic nasal drug delivery with pharmaceutical excipients.
Roméo (1998)
10.1111/j.2042-7158.1994.tb03876.x
Nasal Absorption of Desmopressin in Rats and Sheep. Effect of a Bioadhesive Microsphere Delivery System
H. Critchley (1994)
Sample availability: Not available
10.1016/J.IJPHARM.2007.03.005
Chitosan/cyclodextrin nanoparticles as macromolecular drug delivery system.
A. Krauland (2007)
10.1002/jbm.b.31161
Chitosan-NAC nanoparticles as a vehicle for nasal absorption enhancement of insulin.
X. Wang (2009)
10.1016/J.EJPB.2007.05.008
The addition of calcium ions to starch/Carbopol mixtures enhances the nasal bioavailability of insulin.
E. Pringels (2008)
10.1211/0022357022377
Alkanoylsucroses in nasal delivery of low molecular weight heparins: in‐vivo absorption and reversibility studies in rats
T. Yang (2004)
Development of a freeze-dried formulation of insulin-loaded chitosan nanoparticles intended for nasal administration
R. Fernández-Urrusuno (1999)
10.1016/0168-3659(94)90129-5
Hyaluronic acid ester microspheres as a nasal delivery system for insulin
L. Illum (1994)
Peptide and Protein Drug Delivery Systems for Non-Parenteral Routes of Administration
M. Ingemann (2000)
10.1023/A:1018967116988
Effect of Chitosan on the Permeability of Monolayers of Intestinal Epithelial Cells (Caco-2)
P. Artursson (2004)
10.1002/JPS.2600831212
Epithelial Transport and Bioavailability of Intranasally Administered Human Growth Hormone Formulated with the Absorption Enhancers Didecanoy‐L‐α‐phosphatidylcholine and α‐Cyclodextrin in Rabbits
C. Agerholm (1994)
10.1007/s11095-007-9257-9
Chitosan Reduced Gold Nanoparticles as Novel Carriers for Transmucosal Delivery of Insulin
D. Bhumkar (2007)
10.1016/j.ejpb.2007.12.001
Effective insulin delivery using starch nanoparticles as a potential trans-nasal mucoadhesive carrier.
A. Jain (2008)
10.1016/j.ddtec.2008.11.005
Alternative routes of administration for systemic delivery of protein pharmaceuticals.
E. H. Moeller (2008)
10.1080/02652040400015403
Nasal delivery of insulin using chitosan microspheres
J. Varshosaz (2004)
10.1016/S0928-0987(01)00094-X
Evaluation of gelatin microspheres for nasal and intramuscular administrations of salmon calcitonin.
K. Morimoto (2001)
10.1016/J.YMETH.2005.11.003
Diphtheria toxoid loaded poly-(ε-caprolactone) nanoparticles as mucosal vaccine delivery systems
J. Singh (2006)
10.1586/14760584.6.5.797
Nanoparticles and microparticles as vaccine-delivery systems
M. Singh (2007)
Particulate Drug Delivery; Kumar, M.N.V.R., Ed.; American Scientific Publisher: Stevenson Ranch
Y. Ozsoy (2008)
Peptide and Protein Drug Delivery Systems for Non-Parenteral Routes of Administration. In Pharmaceutical Formulation Development of Peptides and Proteins
M Ingemann (2000)
10.1016/j.addr.2008.09.005
Nanoparticles for nasal vaccination.
N. Csaba (2009)
Novel chitosan-based delivery systems for the nasal administration of a LHRH-analogue
L. Illum (2000)
In vivo studies on nasal preparations of ciprofloxacin hydrochloride.
Y. Ozsoy (2000)
In Handbook of Particulate Drug Delivery
Y Ozsoy
Formulation for delivery the therapeutics proteins
S. Stolnic (2009)
10.3109/10611860108997935
Transport of Nanoparticles Across the Rat Nasal Mucosa
J. Brooking (2001)
10.1016/S0168-3659(01)00486-2
Design of biodegradable particles for protein delivery.
A. Vila (2002)
10.1016/S0264-410X(02)00146-9
Influence of dose and immunization route on the serum Ig G antibody response to BSA loaded PLGA microspheres.
I. Gutierro (2002)
10.1016/J.EJPB.2003.09.006
Low molecular weight chitosan nanoparticles as new carriers for nasal vaccine delivery in mice.
A. Vila (2004)
10.1002/JPS.10171
Nasal administration of low molecular weight heparin.
J. Arnold (2002)
10.1067/MAI.2001.118785
Intranasal heparin reduces eosinophil recruitment after nasal allergen challenge in patients with allergic rhinitis.
C. Vancheri (2001)
10.1016/j.jconrel.2005.09.047
Enhancement of nasal absorption of large molecular weight compounds by combination of mucolytic agent and nonionic surfactant.
T. Matsuyama (2006)
10.1023/A:1011063232257
Tetanus Toxoid Loaded Nanoparticles from Sulfobutylated Poly(Vinyl Alcohol)-Graft-Poly(Lactide-co-Glycolide): Evaluation of Antibody Response After Oral and Nasal Application in Mice
T. Jung (2004)
10.1007/s00223-002-0034-9
Intranasal Delivery of PEGylated Salmon Calcitonins: Hypocalcemic Effects in Rats
K. C. Lee (2002)
10.1211/0022357056073
Effect of chitosan on the intranasal absorption of salmon calcitonin in sheep
M. Hinchcliffe (2005)
10.1016/0378-5173(92)90353-4
In vitro evaluation of mucoadhesive properties of chitosan and some other natural polymers
C. Lehr (1992)
Sample availability: Not available
10.1007/s11095-009-9871-9
Clinical Study Shows Improved Absorption of Desmopressin with Novel Formulation
N. Fransén (2009)
10.1016/J.JCONREL.2006.08.015
Positively charged polyethylenimines enhance nasal absorption of the negatively charged drug, low molecular weight heparin.
T. Yang (2006)
10.1248/BPB.28.2263
Nasal recombinant hirudin-2 delivery: absorption and its mechanism in vivo and in vitro studies.
Y. Zhang (2005)
10.1016/J.JCONREL.2006.03.011
Aminated gelatin microspheres as a nasal delivery system for peptide drugs: evaluation of in vitro release and in vivo insulin absorption in rats.
J. Wang (2006)
10.1016/S0168-3659(00)00369-2
Preparation of desmopressin-containing liposomes for intranasal delivery.
S. Law (2001)
10.1023/A:1012160102740
Chitosans as Absorption Enhancers for Poorly Absorbable Drugs 2: Mechanism of Absorption Enhancement
N. G. Schipper (2004)
10.1023/A:1018911206646
Drug Metabolism in the Nasal Mucosa
Mohamadi A. Sarkar (2004)
10.1201/b19309
Encyclopedia of Pharmaceutical Technology
J. Swarbrick (2006)
10.1016/S0168-3659(97)00193-4
Microparticle resins as a potential nasal drug delivery system for insulin.
M. Takenaga (1998)
10.1016/s0165-6147(96)90065-6
Remington:the science and practice of pharmacy
A. R. Gennaro (1995)
10.1016/S0169-409X(01)00172-7
The nose and paranasal sinuses physiology and anatomy.
N. Jones (2001)
10.1016/S0928-0987(01)00172-5
Chitosan and its derivatives in mucosal drug and vaccine delivery.
I. M. van der Lubben (2001)
Vitro and in Vivo Studies on Ondansetron HCl-Loaded Chitosan Microspheres for Nasal Drug Delivery. 6 th World Meeting on Pharmaceutics
S Gungor (2008)
In Vitro and in Vivo Studies on Ondansetron HCl-Loaded Chitosan Microspheres for Nasal Drug Delivery
S. Gungor (2008)
Intranasal Drug Delivery. In Modified Release Drug Delivery Technology
D P Wermeling (2002)
10.1023/A:1018927710280
Tolerability and Absorption Enhancement of Intranasally Administered Octreotide by Sodium Taurodihydrofusidate in Healthy Subjects
T. Kissel (2004)
10.1007/BF03350260
Intranasal and intramuscular human calcitonin in female osteoporosis and in Paget’s disease of bones: a pilot study
A. Pontiroli (1991)
10.1080/03639040802363704
Formulation and characterization of nanoemulsion-based drug delivery system of risperidone.
M. Kumar (2009)
10.1023/A:1015830907632
The Nasal Mucociliary Clearance: Relevance to Nasal Drug Delivery
N. G. Schipper (2004)
10.1016/S0378-5173(02)00555-0
Influence of multiple nasal administrations of bioadhesive powders on the insulin bioavailability.
C. Callens (2003)
10.1016/S0168-3659(02)00363-2
Nasal drug delivery--possibilities, problems and solutions.
L. Illum (2003)
10.1016/J.JCONREL.2004.08.001
Nasal delivery of human growth hormone: in vitro and in vivo evaluation of a thiomer/glutathione microparticulate delivery system.
V. Leitner (2004)
10.1248/CPB.43.2232
Enhanced nasal delivery of luteinizing hormone releasing hormone agonist buserelin by oleic acid solubilized and stabilized in hydroxypropyl-beta-cyclodextrin.
K. Abe (1995)
10.1002/JPS.20700
In vivo evaluation of a nasal insulin delivery system based on thiolated chitosan.
A. Krauland (2006)
10.2174/187221109787158346
Chitosan and its use in design of insulin delivery system.
T. Wong (2009)
10.1016/0168-3659(90)90016-M
Nasal administration of insulin using bioadhesive microspheres as a delivery system
N. Farraj (1990)
10.1530/EJE.0.1350309
Bioavailability and bioactivity of three different doses of nasal growth hormone (GH) administered to GH-deficient patients: comparison with intravenous and subcutaneous administration.
T. Laursen (1996)
10.1016/j.jconrel.2008.09.076
Effect of cell-penetrating peptides on the nasal absorption of insulin.
E. Khafagy (2009)
10.1016/s0169-409x(01)00162-4
Nasal vaccines.
S. Davis (2001)
Molecules
(2009)
This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution license
10.1016/0378-5173(90)90232-S
Characterization of degradable starch microspheres as a nasal delivery system for drugs
E. Björk (1990)
10.1016/S0378-5173(01)00736-0
Improved nasal bioavailability of elcatonin by insoluble powder formulation.
F. Ishikawa (2001)
Diphtheria toxoid loaded poly-(epsilon-caprolactone) nanoparticles as mucosal vaccine delivery systems.
Jasvinder Singh (2006)
10.1023/A:1018992716621
The Bioavailability of Intranasal Salmon Calcitonin in Healthy Volunteers with and Without a Permeation Enhancer
W. Lee (2004)
Epithelial transport and bioavailability of intranasally administered human growth hormone formulated with the absorption enhancers didecanoyl-L-alpha-phosphatidylcholine and alpha-cyclodextrin in rabbits.
C. Agerholm (1994)
The deposition of solution-based and suspension-based aerosols from metered dose inhalers in healthy subjects and asthmatic patients
P. Sanders (1997)
Absorption enhancers for nasal drug
S. S. Davis (2003)
Absorption of peptides and proteins from the respiratory tract and the potential for development of locally administered vaccine.
D. O'hagan (1990)
10.1016/S0169-409X(01)00164-8
Nasal delivery of epitope based vaccines.
W. Olszewska (2001)
10.1211/0022357011775145
The biopharmaceutical aspects of nasal mucoadhesive drug delivery
M. I. Ugwoke (2001)
10.1152/PHYSREV.00001.2003
Transcytosis: crossing cellular barriers.
P. Tuma (2003)
10.1089/0894268041457183
PEG-PLA nanoparticles as carriers for nasal vaccine delivery.
A. Vila (2004)
10.1210/JCEM.76.4.8473411
Intranasal administration of human growth hormone (hGH) in combination with a membrane permeation enhancer in patients with GH deficiency: a pharmacokinetic study.
L. Hedin (1993)
10.1016/S0378-5173(01)00708-6
Bioadhesive starch microspheres and absorption enhancing agents act synergistically to enhance the nasal absorption of polypeptides.
L. Illum (2001)
Nasal mucosa as an absorption barrier
A. Cornaz (1994)
Mucoadhesive microspheres for controlled drug
K. P. Chowdary (2004)
10.1016/S0378-5173(00)00506-8
Lipid emulsions as vehicles for enhanced nasal delivery of insulin.
R. Mitra (2000)
10.1002/JPS.2600760709
Analysis of structural requirements for the absorption of drugs and macromolecules from the nasal cavity.
C. Mcmartin (1987)
Vitro and in Vivo Studies on Ondansetron HCl-Loaded Chitosan Microspheres for Nasal Drug Delivery. 6 th World Meeting on Pharmaceutics
S Gungor (2008)
10.1016/J.JCONREL.2006.08.004
Improved nasal absorption of salmon calcitonin by powdery formulation with N-acetyl-L-cysteine as a mucolytic agent.
T. Matsuyama (2006)
10.2165/00003088-200342130-00003
Absorption Enhancers for Nasal Drug Delivery
S. Davis (2003)
10.1023/A:1018997625726
Bioavailability of Leuprolide Acetate Following Nasal and Inhalation Delivery to Rats and Healthy Humans
A. Adjei (2004)
10.3109/10837450903148257
Ondansetron-loaded biodegradable microspheres as a nasal sustained delivery system: In vitro/in vivo studies
S. Gungor (2010)
10.1016/0168-3659(92)90018-M
Microspheres as a nasal delivery system for peptide drugs
P. Edman (1992)
10.1016/S0169-409X(97)00060-4
Intranasal drug delivery.
Hussain (1998)
10.1016/S0378-5173(01)00930-9
Nasal glucagon delivery using microcrystalline cellulose in healthy volunteers.
D. Teshima (2002)
10.1016/S1359-6446(02)02452-2
Permeability issues in nasal drug delivery.
P. Arora (2002)
10.1016/0378-5173(95)00070-Y
Dextran microspheres as a potential nasal drug delivery system for insulin : in vitro and in vivo properties
Lena Pereswetoff-Morath (1995)



This paper is referenced by
10.3390/pharmaceutics10020040
In Situ-Based Gels for Nose to Brain Delivery for the Treatment of Neurological Diseases
B. Aderibigbe (2018)
10.1016/j.ijbiomac.2017.12.056
Pramipexole dihydrochloride loaded chitosan nanoparticles for nose to brain delivery: Development, characterization and in vivo anti-Parkinson activity.
Ruhi Raj (2018)
10.1016/j.jconrel.2019.06.021
Nose-to-brain delivery of hyaluronate - FG loop peptide conjugate for Non-invasive hypoxic-ischemic encephalopathy therapy.
Yun Seop Kim (2019)
10.1016/j.neuroscience.2016.01.020
Intranasal insulin protects against substantia nigra dopaminergic neuronal loss and alleviates motor deficits induced by 6-OHDA in rats
Y. Pang (2016)
10.1081/E-EBPP-120050020
Anticancer Agents: Polysaccharide-Based Nanocarriers for Drug Delivery
Raje Chouhan (2015)
10.2174/2210303109666190508083142
Recent Advances and Novel Approaches for Nose to Brain Drug Delivery for Treatment of Migraine
Nidhi Sachan (2019)
10.1007/s11095-011-0392-y
Controlled Delivery Systems: From Pharmaceuticals to Cells and Genes
E. R. Balmayor (2011)
Review on Strategies and Prospective of in Situ Nasal Gel
Jyoti Lokhande (2020)
10.3233/thc-191845
Potentials of human bile acids and their salts in pharmaceutical nano delivery and formulations adjuvants.
S. Kecman (2019)
10.1007/s10571-015-0199-1
Protective Effect of Tat PTD-Hsp27 Fusion Protein on Tau Hyperphosphorylation Induced by Okadaic Acid in the Human Neuroblastoma Cell Line SH-SY5Y
Sunghyun Choi (2015)
PSAA encapsulated mucoadhesive polycaprolactone microparticles as potential intranasal vaccine delivery system against pneumococcal infections / by Yamini Gorantla
Yamini Gorantla (2017)
10.1016/J.JDDST.2017.06.018
Advances on the formulation of proteins using nanotechnologies
Irene Santalices (2017)
10.1007/s11095-016-1929-x
Rapid Absorption of Dry-Powder Intranasal Oxytocin
Mikolaj Milewski (2016)
10.2174/1567201816666191029122740
Drug delivery and targeting to the brain through nasal route: Mechanisms, Applications and Challenges.
Kanchan Kashyap (2019)
10.1007/978-3-030-35910-2
Mucosal Delivery of Drugs and Biologics in Nanoparticles
Pavan Muttil (2020)
10.1371/journal.pone.0124777
The Role of Alveolar Epithelial Type II-Like Cells in Uptake of Structurally Different Antigens and in Polarisation of Local Immune Responses
Johnnie Akgün (2015)
10.4155/TDE.12.79
Peptide therapeutics: it's all in the delivery.
Marshall Grant (2012)
10.1016/j.jconrel.2012.05.040
Recent advances in nanocarrier-based mucosal delivery of biomolecules.
Olga Kammona (2012)
10.1016/j.ijpharm.2016.09.086
Application of RPMI 2650 as a cell model to evaluate solid formulations for intranasal delivery of drugs.
V. S. Gonçalves (2016)
A preliminary study of intranasal epinephrine administration as a potential route for anaphylaxis treatment.
C. Srisawat (2016)
10.2478/s11532-012-0021-6
Bioanalysis of small-molecule drugs in nasal and paranasal tissues and secretions: Current status and perspectives
Ana Serralheiro (2012)
10.1016/j.jconrel.2013.06.010
On employing a translationally controlled tumor protein-derived protein transduction domain analog for transmucosal delivery of drugs.
Hae-duck Bae (2013)
10.1517/17425247.2011.588204
Intranasal delivery of therapeutic proteins for neurological diseases
F. Malerba (2011)
10.2174/1567201815666181011121750
Formulation and Evaluation of Neuroactive Drug Loaded Chitosan Nanoparticle for Nose to Brain Delivery: In-vitro Characterization and In-vivo Behavior Study.
Mohsin Qureshi (2019)
Exploration of an electro-magneto-responsive polymeric drug delivery system for enhanced nose-to-brain delivery
O. D. Akilo (2016)
10.24377/LJMU.T.00004462
DRY POWDER INHALATION OF PNEUMOCOCCAL VACCINE USING POLYMERIC NANOPARTICLES AS CARRIERS
N. Kunda (2014)
10.1016/j.ijpharm.2019.118592
Modified chitosan-based nanoadjuvants enhance immunogenicity of protein antigens after mucosal vaccination.
Genada Sinani (2019)
10.1007/s12247-018-9343-z
Lamotrigine Lipid Nanoparticles for Effective Treatment of Epilepsy: a Focus on Brain Targeting via Nasal Route
Puja K. Gangurde (2018)
10.3390/molecules200814451
Absorption-Enhancing Effects of Bile Salts
E. Moghimipour (2015)
10.1016/j.jchromb.2018.09.018
Analytical method development of methylisothiazolinone, a preservative, in rat plasma using LC-MS/MS.
Hyang Yeon Kim (2018)
INTRANASAL CHITOSAN MICROSPHERES FOR THE TREATMENT OF EPILEPSY
J. B. Taksande (2017)
Evaluation of intranasal canine parvovirus vaccination in dogs
Murugesan (2010)
See more
Semantic Scholar Logo Some data provided by SemanticScholar